Glycemic and Insulinemic Response to Oats Soaked Overnight in Milk Compared to Cream of Rice in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toronto, Canada
- Glycemic Index Laboratories
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male or non-pregnant females, 18-75 years of age, inclusive
- Body mass index (BMI) between 20.00 and 34.99 kg/m² inclusive at screening (visit 1).
- Willing to maintain habitual diet, physical activity pattern, and body weight throughout the trial and to refrain from smoking for 12hr prior to each visit.
- Willing to maintain current dietary supplement use throughout the trial. On test days, subject agrees not to take any dietary supplements until dismissal from the GI labs. Failure to comply will result in a rescheduled test visit.
- Normal fasting serum glucose (<7.0mmol/L capillary corresponding to whole blood glucose <6.3mmol/L).
- Willing to abstain from alcohol consumption and avoid vigorous physical activity for 24 h prior to all test visits.
- Absence of health conditions that would prevent fulfillment of study requirements as judged by the Investigator on the basis of medical history.
- Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator.
Exclusion Criteria:
- Failure to meet any one of the inclusion criteria
- Known history of AIDS, hepatitis, a history or presence of clinically important endocrine (including Type 1 or Type 2 diabetes mellitus), cardiovascular (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), pulmonary, biliary or GI disorders.
- Use of medications known to influence carbohydrate metabolism, including, but not limited to adrenergic blockers, diuretics, thiazolidinediones, metformin and systemic corticosteroids within 4 weeks of the screening visit, or with any condition which might, in the opinion of Dr. Wolever, the president of GI Testing, either: 1) make participation dangerous to the subject or to others, or 2) affect the results.
- Major trauma or surgical event within 3 months of screening.
- Unwillingness or inability to comply with the experimental procedures and to follow GI Labs safety guidelines.
- Known intolerance, sensitivity or allergy to any ingredients in the study products.
- Extreme dietary habits, as judged by the Investigator (i.e. Atkins diet, very high protein diets, etc.).
- Uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg as defined by the average blood pressure measured at screening.
- Change in body weight of >3.5kg within 4 weeks of the screening visit.
- Presence of any signs or symptoms of an active infection within 5 d prior to any test visit. If an infection occurs during the study period, test visits should be rescheduled until all signs and symptoms have resolved and any treatment (i.e. antibiotic therapy) has been completed at least 5 d prior to each test visit.
- History of cancer in the prior two years, except for non-melanoma skin cancer.
- Recent history (within 12 months of screening) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as > 14 drinks per week (1 drink=12 oz beer, 5 oz wine, or 1.5 oz distilled spirits).
- Exposure to any non-registered drug product within 30 d prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Overnight Oats
40 g of overnight oats
|
Consumption of one cereal in the beginning of each visit
Other Names:
|
|
PLACEBO_COMPARATOR: Soaked Cream of Rice
28.8 cream of rice
|
Consumption of one cereal in the beginning of each visit
Other Names:
|
|
PLACEBO_COMPARATOR: Cooked Cream of Rice
28.8 cooked cream of rice
|
Consumption of one cereal in the beginning of each visit
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incremental area under the blood glucose curve
Time Frame: 0-2 hours
|
0-2 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
incremental areas under the curve of blood glucose from 2-3h
Time Frame: 2-3 hours
|
2-3 hours
|
|
incremental areas under the curve of blood glucose from 0-3h
Time Frame: 0-3 hours
|
0-3 hours
|
|
incremental areas under the curve of insulin serum 0-2 hours
Time Frame: 0-2 hours
|
0-2 hours
|
|
incremental areas under the curve of insulin serum 2-3 hours
Time Frame: 2-3 hours
|
2-3 hours
|
|
incremental areas under the curve of insulin serum 0-3 hours
Time Frame: 0-3 hours
|
0-3 hours
|
|
peak concentrations and peak rises of glucose and insulin
Time Frame: 0-3 hours
|
0-3 hours
|
|
blood glucose and insulin concentrations and increments at each time point over a 3hr period
Time Frame: 0-3 hours
|
0-3 hours
|
|
netAUC of the curves for fullness, hunger, desire to eat, prospective consumption and average appetite over 0-2hr and 0-3hr
Time Frame: 0-2 hour and 0-3 hours
|
0-2 hour and 0-3 hours
|
|
self reports of fullness, hunger, desire to eat, prospective consumption and average appetite at each point in time via questionnaires
Time Frame: 3 hours post consumption
|
3 hours post consumption
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- PEP-1610
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glycemic, Insulinemic, Subjective Appetite Responses
-
NCT03495778CompletedGlycemic | Insulinemic | Subjective Hunger Responses
-
NCT01926431CompletedNeural Responses | Appetite Hormones | Subjective Appetite Sensations
-
NCT07505680CompletedCircadian Rhythm | Appetite | Metabolic Health | Body Weight Control | Glycemic and Insulinemic Response
-
NCT05279183CompletedGastrointestinal Hormones | Glycemic Control | Appetite | Satiation | Reward Responses | Emotional State
-
NCT02197195CompletedGlycemic Control | Subjective Appetite
-
NCT03165773CompletedGlycemic and Insulinemic Response
-
NCT03298529CompletedHealthy Subjects | Glycemic Response | Insulinemic Response
-
NCT03491514CompletedGlycemic Response | Insulinemic Response | Subjectvie Hunger
-
NCT06005415CompletedPostprandial Glycemic Responses
Clinical Trials on Cereal - oats
-
NCT02506972Completed
-
NCT07045051Recruiting
-
NCT06108505Active, not recruiting
-
NCT02655367Completed
-
NCT04021303UnknownGastrointestinal Disorder | Immunologic Diseases in Children
-
NCT05803408RecruitingCeliac Disease | Gluten Sensitivity | Gluten Enteropathy | Gluten Allergy
-
NCT02612766Completed
-
NCT04176614CompletedOverweight and Obesity
-
NCT01711008CompletedAlteration of Cognitive Function